US Bancorp DE Lowers Stock Holdings in Edwards Lifesciences Co. (NYSE:EW)

US Bancorp DE trimmed its position in Edwards Lifesciences Co. (NYSE:EW) by 7.9% during the first quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 762,467 shares of the medical research company’s stock after selling 65,373 shares during the quarter. US Bancorp DE owned approximately 0.13% of Edwards Lifesciences worth $72,861,000 at the end of the most recent quarter.

Other institutional investors also recently modified their holdings of the company. Martin Capital Advisors LLP raised its position in shares of Edwards Lifesciences by 0.5% in the 4th quarter. Martin Capital Advisors LLP now owns 25,490 shares of the medical research company’s stock worth $1,944,000 after purchasing an additional 128 shares during the last quarter. Legacy Wealth Asset Management LLC increased its holdings in Edwards Lifesciences by 0.8% in the 4th quarter. Legacy Wealth Asset Management LLC now owns 16,958 shares of the medical research company’s stock worth $1,293,000 after buying an additional 134 shares in the last quarter. Chapin Davis Inc. increased its holdings in Edwards Lifesciences by 1.7% in the 1st quarter. Chapin Davis Inc. now owns 8,548 shares of the medical research company’s stock worth $817,000 after buying an additional 140 shares in the last quarter. Johnson Financial Group Inc. increased its holdings in Edwards Lifesciences by 23.0% in the 4th quarter. Johnson Financial Group Inc. now owns 771 shares of the medical research company’s stock worth $59,000 after buying an additional 144 shares in the last quarter. Finally, Valley National Advisers Inc. increased its holdings in Edwards Lifesciences by 6.0% in the 1st quarter. Valley National Advisers Inc. now owns 2,677 shares of the medical research company’s stock worth $255,000 after buying an additional 152 shares in the last quarter. 79.46% of the stock is currently owned by institutional investors.

Insider Transactions at Edwards Lifesciences

In other news, CEO Bernard J. Zovighian bought 580 shares of the stock in a transaction dated Monday, May 6th. The stock was purchased at an average cost of $85.74 per share, for a total transaction of $49,729.20. Following the transaction, the chief executive officer now owns 3,268 shares of the company’s stock, valued at $280,198.32. The purchase was disclosed in a filing with the SEC, which can be accessed through this link. In other news, CEO Bernard J. Zovighian bought 580 shares of the stock in a transaction dated Monday, May 6th. The stock was purchased at an average cost of $85.74 per share, for a total transaction of $49,729.20. Following the transaction, the chief executive officer now owns 3,268 shares of the company’s stock, valued at $280,198.32. The purchase was disclosed in a filing with the SEC, which can be accessed through this link. Also, CEO Bernard J. Zovighian sold 8,617 shares of the stock in a transaction that occurred on Thursday, May 30th. The shares were sold at an average price of $87.68, for a total value of $755,538.56. Following the transaction, the chief executive officer now owns 68,218 shares of the company’s stock, valued at $5,981,354.24. The disclosure for this sale can be found here. Insiders have sold 81,099 shares of company stock valued at $7,003,553 in the last ninety days. Corporate insiders own 1.29% of the company’s stock.

Analyst Ratings Changes

Several equities research analysts recently commented on EW shares. Barclays lifted their price objective on Edwards Lifesciences from $100.00 to $101.00 and gave the stock an “overweight” rating in a report on Tuesday, May 7th. Oppenheimer lifted their price objective on Edwards Lifesciences from $93.00 to $100.00 and gave the stock an “outperform” rating in a report on Monday, March 18th. Piper Sandler lifted their price objective on Edwards Lifesciences from $85.00 to $88.00 and gave the stock a “neutral” rating in a report on Friday, April 26th. Wells Fargo & Company lifted their price objective on Edwards Lifesciences from $94.00 to $99.00 and gave the stock an “overweight” rating in a report on Friday, April 26th. Finally, Morgan Stanley boosted their price target on Edwards Lifesciences from $95.00 to $103.00 and gave the company an “overweight” rating in a research note on Thursday, March 21st. One investment analyst has rated the stock with a sell rating, five have issued a hold rating and fifteen have issued a buy rating to the stock. According to MarketBeat, Edwards Lifesciences has an average rating of “Moderate Buy” and a consensus target price of $96.76.

Edwards Lifesciences Price Performance

NYSE EW traded down $1.77 during trading hours on Tuesday, reaching $87.73. The company’s stock had a trading volume of 4,418,165 shares, compared to its average volume of 3,404,045. The firm’s 50-day moving average price is $89.06 and its 200-day moving average price is $86.60. The company has a quick ratio of 2.67, a current ratio of 3.75 and a debt-to-equity ratio of 0.08. Edwards Lifesciences Co. has a 1 year low of $60.57 and a 1 year high of $96.12. The company has a market capitalization of $52.87 billion, a price-to-earnings ratio of 38.39, a PEG ratio of 3.33 and a beta of 1.11.

Edwards Lifesciences (NYSE:EW) last posted its quarterly earnings results on Thursday, April 25th. The medical research company reported $0.66 EPS for the quarter, topping analysts’ consensus estimates of $0.64 by $0.02. Edwards Lifesciences had a return on equity of 22.86% and a net margin of 23.01%. The company had revenue of $1.60 billion for the quarter, compared to analysts’ expectations of $1.58 billion. On average, equities research analysts predict that Edwards Lifesciences Co. will post 2.77 EPS for the current fiscal year.

About Edwards Lifesciences

Edwards Lifesciences Corporation provides products and technologies for structural heart disease and critical care monitoring in the United States, Europe, Japan, and internationally. It offers transcatheter heart valve replacement products for the minimally invasive replacement of aortic heart valves under the Edwards SAPIEN family of valves system; and transcatheter heart valve repair and replacement products to treat mitral and tricuspid valve diseases under the PASCAL PRECISION and Cardioband names.